Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer.
Brems-Eskildsen AS, Linnet S, Danø H, Luczak A, Vestlev PM, Jakobsen EH, Neimann J, Jensen CB, Dongsgaard T, Langkjer ST. Brems-Eskildsen AS, et al. Acta Oncol. 2021 Feb;60(2):157-164. doi: 10.1080/0284186X.2020.1851045. Epub 2020 Dec 1. Acta Oncol. 2021. PMID: 33259244 Clinical Trial.
The NAME trial: a direct comparison of classical oral Navelbine versus Metronomic Navelbine in metastatic breast cancer.
Langkjer ST, Kenholm J, Jensen JD, Wedervang K, Brixen AT, Grunnet M, Stenbygaard L, Gilje B, Danø H, Glavicic V, Jacobsen EH, Brems-Eskildsen AS, Kruse HL, Dongsgaard T, Neimann J, Geisler J. Langkjer ST, et al. Among authors: brems eskildsen as. Future Oncol. 2019 Aug;15(22):2561-2569. doi: 10.2217/fon-2019-0124. Epub 2019 Jun 19. Future Oncol. 2019. PMID: 31215242 Free article. Clinical Trial.
Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer.
Laurberg JR, Brems-Eskildsen AS, Nordentoft I, Fristrup N, Schepeler T, Ulhøi BP, Agerbaek M, Hartmann A, Bertz S, Wittlinger M, Fietkau R, Rödel C, Borre M, Jensen JB, Orntoft T, Dyrskjøt L. Laurberg JR, et al. Among authors: brems eskildsen as. BJU Int. 2012 Dec;110(11 Pt C):E1228-36. doi: 10.1111/j.1464-410X.2012.11564.x. Epub 2012 Oct 9. BJU Int. 2012. PMID: 23046361
Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis.
Thorsen K, Sørensen KD, Brems-Eskildsen AS, Modin C, Gaustadnes M, Hein AM, Kruhøffer M, Laurberg S, Borre M, Wang K, Brunak S, Krainer AR, Tørring N, Dyrskjøt L, Andersen CL, Orntoft TF. Thorsen K, et al. Among authors: brems eskildsen as. Mol Cell Proteomics. 2008 Jul;7(7):1214-24. doi: 10.1074/mcp.M700590-MCP200. Epub 2008 Mar 18. Mol Cell Proteomics. 2008. PMID: 18353764 Free article.
A combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor models.
Bohn AB, Wittenborn T, Brems-Eskildsen AS, Laurberg T, Bertelsen LB, Nielsen T, Stødkilde-Jørgensen H, Møller BK, Horsman MR. Bohn AB, et al. Among authors: brems eskildsen as. PLoS One. 2014 Oct 9;9(10):e110091. doi: 10.1371/journal.pone.0110091. eCollection 2014. PLoS One. 2014. PMID: 25299269 Free PMC article.
Low ANXA10 expression is associated with disease aggressiveness in bladder cancer.
Munksgaard PP, Mansilla F, Brems Eskildsen AS, Fristrup N, Birkenkamp-Demtröder K, Ulhøi BP, Borre M, Agerbæk M, Hermann GG, Orntoft TF, Dyrskjøt L. Munksgaard PP, et al. Among authors: brems eskildsen as. Br J Cancer. 2011 Oct 25;105(9):1379-87. doi: 10.1038/bjc.2011.404. Epub 2011 Oct 6. Br J Cancer. 2011. PMID: 21979422 Free PMC article.